A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Latest Information Update: 14 Oct 2021
At a glance
- Drugs Vixtimotamab (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amphivena Therapeutics
- 11 Oct 2021 Status changed from active, no longer recruiting to completed.
- 21 May 2020 Planned End Date changed from 1 Jun 2020 to 1 Jul 2020.
- 21 May 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Jul 2020.